Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study

Approval of the study was obtained from the hospital's ethical committee. The study design and methodology followed the tenets of Declaration of Helsinki. All patients were provided with written informed consent and received a thorough explanation of the study design, aims, and the off-label use of infliximab, its potential risks, and benefits. This is a prospective non-comparative interventional study. The study was conducted on 20 eyes of 20 patients with refractory posterior uveitis in Behçet's disease who received 3 consecutive intravitreal injections of infliximab (1 mg/0.05 ml) 6 weeks apart. Behçet's diseases was diagnosed based on the International Criteria for Behçet's Disease (ICBD).

Patients were subjected to the following initial examinations: best-corrected visual acuity (BCVA) measurement; slit-Lamp examination; measuring intraocular pressure (IOP) by Goldman applanation tonometry; dilated fundus examination by indirect ophthalmoscope; and slit-lamp biomicroscopy including vitritis grading (0-4) and presence or absence of vasculitis, retinitis and papillopathy. Patients also had the following at baseline: fluorescein angiography (FFA), ERG, and central foveal thickness (CFT) OCT (Stratus III OCT; Carl Zeiss, Dublin, CA). Grading of vitritis was as follows: Grade 0: Good view of NFL (nerve fibre layer), Grade +1: clear optic nerve & vessels but hazy NFL, Grade +2: optic nerve & vessels are hazy, Grade +3: view of optic nerve only, and Grade +4: no optic nerve view.

Follow up clinical examinations were at day 1, and weeks 2, 4, 6, 8, 12 and 18. Each follow up visit included: BCVA, slit-Lamp examination, IOP, dilated fundus examination with grading of vitritis (0-4), and presence or absence of vasculitis, retinitis or papillopathy. CFT OCT, and ERG were done at 4, 12 and 18 weeks. FFA was done at the discretion of the examiner and not at every post-injection evaluation.

The intravitreal dose of infliximab used in this study is 1mg/0.05ml. Animal studies have shown intravitreal infliximab in doses up to 2mg is safe clinically, and by electrophysiological and histopathological examinations. These findings were maintained for 3 months with 3 monthly injections. However, in clinical trial severe intraocular inflammation was elicited with even a single low dose of 0.5mg in non-uveitic eyes. Since the 1 mg dose was shown to be effective in controlling inflammation in one study, we decided to use this dose and avoid the 1.5mg and the 2mg doses.

Drug preparation: A vial containing 100 mg of commercially available infliximab powder (Remicade Janssen Pharmaceutical Egypt) was reconstituted with 5 mL of sterile water, and 0.05 mL of this solution (1mg of infliximab) used for each patient and placed in a tuberculin syringe using aseptic techniques. The remaining syringes will be kept in a sterile package at 2-8ºC for 6 weeks.